Cell contact-dependent priming and FC interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response

Journal of Immunology

Volumn 192, Issue 5, 2014, Pages 2091-2098

  Bartholomaeus, Patrick ^a   Semmler, Linda Y ^a   Bukur, Thomas ^b,c   Boisguerin, Valesca ^b   Romer, Paula S ^d,e   Tabares, Paula ^d   Chuvpilo, Sergey ^e   Tyrsin, Dmitry Y ^e   Matske Victoriah, Alexey ^e   Hengel, Hartmut ^f   Castle, John ^b   Hunig, Thomas ^d   Kalinke, Ulrich ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e TheraMAB   (Russian Federation)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD32 ANTIGEN; CYTOKINE; FC RECEPTOR; FC RECEPTOR IIB; IMMUNOGLOBULIN G4; TGN 1412; TRANSCRIPTOME;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MOLECULAR DYNAMICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MALE; RECEPTORS, IGG; TRANSCRIPTOME;

EID: 84896514032     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302461     Document Type: Article

References (42)

1. Hünig, T., and K. Dennehy. 2005. CD28 superagonists: mode of action and therapeutic potential. Immunol. Lett. 100: 21-28.
2. Beyersdorf, N., S. Gaupp, K. Balbach, J. Schmidt, K. V. Toyka, C. H. Lin, T. Hanke, T. Hünig, T. Kerkau, and R. Gold. 2005. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. 202: 445-455.
3. Rodríguez-Palmero, M., A. Franch, M. Castell, C. Pelegrí, F. J. Pérez-Cano, C. Kleinschnitz, G. Stoll, T. Hünig, and C. Castellote. 2006. Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody. J. Rheumatol. 33: 110-118.
4. Schmidt, J., K. Elflein, M. Stienekemeier, M. Rodriguez-Palmero, C. Schneider, K. V. Toyka, R. Gold, and T. Hünig. 2003. Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J. Neuroimmunol. 140: 143-152.
5. Beyersdorf, N., T. Hanke, T. Kerkau, and T. Hünig. 2006. CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells. Autoimmun. Rev. 5: 40-45.
6. TeGenero, A. G. TGN1412 investigational medicinal product dossier. Available at: www.circare.org/foia5/tgn1412dossier.pdf.
7. Gibbs, R. A., J. Rogers, M. G. Katze, R. Bumgarner, G. M. Weinstock, E. R. Mardis, K. A. Remington, R. L. Strausberg, J. C. Venter, R. K. Wilson, et al; Rhesus Macaque Genome Sequencing and Analysis Consortium. 2007. Evolutionary and biomedical insights from the rhesus macaque genome. Science 316: 222-234.
8. Waibler, Z., L. Y. Sender, C. Merten, R. Hartig, S. Kliche, M. Gunzer, P. Reichardt, U. Kalinke, and B. Schraven. 2008. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PloS One 3: e1708.
9. Suntharalingam, G., M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, and N. Panoskaltsis. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355: 1018-1028.
10. Duff, G. 2006. Expert group on phase one clinical trials: final report. Available at: http://webarchive.nationalarchives.gov.uk/20130107105354/http:// www.dh. gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/ DH-063117.
11. Eastwood, D., L. Findlay, S. Poole, C. Bird, M. Wadhwa, M. Moore, C. Burns, R. Thorpe, and R. Stebbings. 2010. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br. J. Pharmacol. 161: 512-526.
12. European Medicines Agency. 2007. Guideline on strategies to identify and mitigate risk for first-in human clinical trials with investigational medicinal products. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500002988.pdf.
13. Rogers, K. A., F. Scinicariello, and R. Attanasio. 2006. IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions. J. Immunol. 177: 3848-3856.
14. Jacobsen, F. W., R. Padaki, A. E. Morris, T. L. Aldrich, R. J. Armitage, M. J. Allen, J. C. Lavallee, and T. Arora. 2011. Molecular and functional characterization of cynomolgus monkey IgG subclasses. J. Immunol. 186: 341-349.
15. Warncke, M., T. Calzascia, M. Coulot, N. Balke, R. Touil, F. Kolbinger, and C. Heusser. 2012. Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. J. Immunol. 188: 4405-4411.
16. Stebbings, R., L. Findlay, C. Edwards, D. Eastwood, C. Bird, D. North, Y. Mistry, P. Dilger, E. Liefooghe, I. Cludts, et al. 2007. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 179: 3325-3331.
17. Findlay, L., D. Eastwood, R. Stebbings, G. Sharp, Y. Mistry, C. Ball, J. Hood, R. Thorpe, and S. Poole. 2010. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J. Immunol. Methods 352: 1-12.
18. Weissmüller, S., L. Y. Semmler, U. Kalinke, S. Christians, J. Müller-Berghaus, and Z. Waibler. 2012. ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation. Blood 119: 6268-6277.
19. Römer, P. S., S. Berr, E. Avota, S. Y. Na, M. Battaglia, I. ten Berge, H. Einsele, and T. Hünig. 2011. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 118: 6772-6782.
20. Randriamampita, C., G. Boulla, P. Revy, F. Lemaitre, and A. Trautmann. 2003. T cell adhesion lowers the threshold for antigen detection. Eur. J. Immunol. 33: 1215-1223.
21. Stefanová, I., J. R. Dorfman, and R. N. Germain. 2002. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 420: 429-434.
22. Germain, R. N., I. Stefanova, and J. Dorfman. 2002. Self-recognition and the regulation of CD4+ T cell survival. Adv. Exp. Med. Biol. 512: 97-105.
23. International Human Genome Sequencing Consortium. 2004. Finishing the euchromatic sequence of the human genome. Nature 431: 931-945.
24. Langmead, B., C. Trapnell, M. Pop, and S. L. Salzberg. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10: R25.
25. Hsu, F., W. J. Kent, H. Clawson, R. M. Kuhn, M. Diekhans, and D. Haussler. 2006. The UCSC known genes. Bioinformatics 22: 1036-1046.
26. Mortazavi, A., B. A. Williams, K. McCue, L. Schaeffer, and B. Wold. 2008. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5: 621-628.
27. R Development Core Team. 2011. R: A language and environment for statistical computing. Available at: http://www.R-project.org/
28. Anders, S., and W. Huber. 2010. Differential expression analysis for sequence count data. Genome Biol. 11: R106.
29. Bruhns, P. 2012. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119: 5640-5649.
30. Boruchov, A. M., G. Heller, M. C. Veri, E. Bonvini, J. V. Ravetch, and J. W. Young. 2005. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115: 2914-2923.
31. Veri, M. C., S. Gorlatov, H. Li, S. Burke, S. Johnson, J. Stavenhagen, K. E. Stein, E. Bonvini, and S. Koenig. 2007. Monoclonal antibodies capable of discriminating the human inhibitory Fcg-receptor IIB (CD32B) from the activating Fcgreceptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121: 392-404.
32. Rossi, E. A., D. M. Goldenberg, R. Michel, D. L. Rossi, D. J. Wallace, and C. H. Chang. 2013. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood 122: 3020-3029.
33. Corrales-Aguilar, E., M. Trilling, H. Reinhard, E. Mercé- Maldonado, M.Widera, H. Schaal, A. Zimmermann, O. Mandelboim, and H. Hengel. 2013. A novel assay for detecting virus-specific antibodies triggering activation of Fcg receptors. J. Immunol. Methods 387: 21-35.
34. Eastwood, D., C. Bird, P. Dilger, J. Hockley, L. Findlay, S. Poole, S. J. Thorpe, M. Wadhwa, R. Thorpe, and R. Stebbings. 2013. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br. J. Clin. Pharmacol. 76: 299-315.
35. Rajasekaran, K., V. Xiong, L. Fong, J. Gorski, and S. Malarkannan. 2010. Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells. PloS One 5: e12635.
36. Hansel, T. T., H. Kropshofer, T. Singer, J. A. Mitchell, and A. J. George. 2010. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9: 325-338.
37. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daeron. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
38. Hanke, T., M. Trischler, and C. Guntermann, inventors. Nucleic acids encoding superagonistic anti-CD28 antibodies. United States patent no. 7,585,960. 2008 Sep 9.
39. Sada-Ovalle, I., A. Talayero, L. Chavéz-Galán, L. Barrera, A. Castorena-Maldonado, A. Soda-Merhy, and L. Torre-Bouscoulet. 2012. Functionality of CD4+ and CD8+ T cells from tonsillar tissue. Clin. Exp. Immunol. 168: 200-206.
40. Ball, C., B. Fox, S. Hufton, G. Sharp, S. Poole, R. Stebbings, D. Eastwood, L. Findlay, P. W. Parren, R. Thorpe, et al. 2012. Antibody C region influences TGN1412-like functional activity in vitro. J. Immunol. 189: 5831-5840.
41. O'Connell, R. M., D. Kahn, W. S. Gibson, J. L. Round, R. L. Scholz, A. A. Chaudhuri, M. E. Kahn, D. S. Rao, and D. Baltimore. 2010. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33: 607-619.
42. Baumjohann, D., and K. M. Ansel. 2013. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nat. Rev. Immunol. 13: 666-678.